Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon is attractive because its first-in-class C1q inhibition targets the initiating step of the classical complement pathway, offering a differentiated mechanism that could preserve efficacy while reducing the safety trade-offs seen with downstream complement drugs. The lead assets provide multiple shots on goal: tanruprubart has Phase 3 evidence in GBS with rapid functional improvement, a clean safety profile, and a BLA submission expected in 4Q26, while vonaprument’s 659-patient ARCHER II study in GA has topline expected in 4Q26 and could validate vision preservation as a commercially meaningful endpoint. Fundamental value is supported by sizable addressable markets and the current disconnect between valuation and pipeline potential, with cited EV around $0.74B versus modeled program values implying materially higher upside if either program advances.

Annexon is viewed negatively because its lead asset vonaprument already missed the Phase 2 ARCHER primary endpoint on GA lesion growth, and the reported vision-preservation signal appears fragile given BCVA noise, a sizable 10-14 letter loss bucket, and the need for a difficult 15-month Phase 3 replication. The company also faces intense commercial and competitive risk, with no approved products, entrenched GA rivals Izervay and Syfovre, and a challenging hospital launch path for tanruprubart in GBS, where no drugs are approved. Financially, it ended 1Q26 with $225M in cash and runway into 2H27, but continued net losses and possible dilutive capital raises could pressure valuation if the 4Q26 readout disappoints.